Award
NIH Reporter #5P01CA018029-49
Transgenic T cell Therapy for Acute Myeloid Leukemia
Recipient
Not specified
Award Amount
$957,908.00
Ceiling
$957,908.00
Awarded
September 22, 2025
Identifier
5P01CA018029-49
Award for clinical trial research on genetically engineered T cells targeting Acute Myeloid Leukemia, funded by the National Cancer Institute with an amount of $957,908.
Description
The project involves clinical trial research on genetically engineered T cells targeting AML. The project aims to improve treatment options for AML patients ineligible for stem cell transplants. It is funded by the National Cancer Institute with a total award amount of $957,908.